Painkiller inquiry could aid Zogenix

The FDA wants to look over painkillers that include the ingredient known as hydrocodone amid an increase in abuse and federal drug agents' ongoing call for stricter prescribing guidelines, Bloomberg reported. The inquiry could lead to a change in the classification of the drug on the government's schedule of controlled substances, leveling the playing field for drug developer Zogenix's developmental form of hydrocodone in the market, where generic forms of the drug are contenders. Article

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.